Agenda - EMA Methodology Working Party (MWP) interested parties meeting 2026

Human medicines European public assessment report (EPAR): Beromun, tasonermin, Date of authorisation: 12/04/1999, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Vizimpro, dacomitinib, Date of authorisation: 02/04/2019, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Iressa, gefitinib, Date of authorisation: 24/06/2009, Revision: 16, Status: Authorised

EMA Methodology Working Party interested parties meeting 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 4 November 2026, 13:00 (CET) to 4 November 2026, 16:00 (CET)

Data quality framework for medicines regulation

Draft Data Quality Framework (DQF) for EU medicines regulation: application to collection, management and submission of Adverse Drug Reaction reports

Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Vgenfli, aflibercept, Date of authorisation: 14/08/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Pavblu, aflibercept, Revision: 3, Status: Authorised